ArticleThe Journal of dermatological treatment2013
How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center.
Article in The Journal of dermatological treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.The patient · 2018Pooled it
- Unmet needs in the management of psoriasis in Latin America: a systematic review.Anais brasileiros de dermatologiaPooled it
- Management of Guttate Psoriasis: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program.Scientific reports · 2024Article
- Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017.The British journal of dermatology · 2019Article
- Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.Patient preference and adherence · 2018Review
- Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study.Advances in therapy · 2017Article
- A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus.Journal of the European Academy of Dermatology and Venereology : JEADV · 2015Review
- Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.The Journal of investigative dermatology · 2015Article
- Psoriasis in childhood: effective strategies to improve treatment adherence.Psoriasis (Auckland, N.Z.) · 2015Review
- An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Dermatologic therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, the potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p = 0.01), lower income level (p = 0.007), and lack of insurance (p = 0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cut backs in personal expenses due to co-payments (p = 0.001). Among respondents, the mean annual out-of-pocket expense for a biologic was $557.12 per year, with a range of $0-7000.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.